Welcome to our dedicated page for Serina Therapeutics news (Ticker: SER), a resource for investors and traders seeking the latest updates and insights on Serina Therapeutics stock.
Serina Therapeutics, Inc. (SER) news is centered on a clinical-stage biotechnology company developing the POZ Platform™ drug optimization technology and SER-252 for advanced Parkinson’s disease. Company updates often focus on clinical study progress, safety monitoring, tolerability observations, pharmacokinetic findings, and exploratory measures related to motor function.
The most important Serina news themes involve the Phase 1b registrational study of SER-252, including cohort dosing, Safety Monitoring Committee review, dose-escalation decisions, and observations tied to sustained apomorphine exposure. Because SER-252 is the company’s main named product candidate, clinical updates are closely tied to how the POZ Platform is being tested in a neurological disease setting.
Serina also reports financial results and business updates, securities financing activity, board and governance changes, and biotechnology conference participation. Research-related announcements may include POZ Platform applications across small molecules, RNA-based therapeutics, antibody-based drug conjugates, and lipid nanoparticle delivery formulations. Company materials also discuss partnership routes such as out-licensing, co-development, and a non-exclusive Pfizer license involving POZ polymer technology for lipid nanoparticle drug delivery formulations.
For SER stock research, key news categories include SER-252 clinical development, POZ Platform research, regulatory and financing disclosures, and corporate updates that affect how the company advances its wholly owned drug candidates and external platform applications.
Serina Therapeutics (SER)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference, with CEO Steve Ledger delivering the presentation. The conference will be held September 14-16, 2026, in New York, New York, and the company will also participate in one-on-one investor meetings during the event.The presentation will be available for on-demand viewing starting Monday, September 14, 2026, at 7:00 a.m. ET via an online link. Serina is a clinical-stage biotechnology company developing wholly owned drug candidates using its proprietary POZ Platform™ drug optimization technology to treat neurological diseases and other indications. The lead program, SER-252 (POZ-apomorphine), is in development as a long-acting treatment for advanced Parkinson’s disease.
Serina Therapeutics (SER) reported blinded Cohort 1 observations from its ongoing Phase 1b registrational study of SER-252 in advanced Parkinson’s disease and will advance to Cohort 2.
The independent Safety Monitoring Committee completed a blinded review of safety and tolerability data from the first cohort, which evaluated the lowest single-ascending-dose level, and recommended dose escalation. Blinded pharmacokinetic observations at this starting dose were consistent with the sustained apomorphine exposure SER-252 is designed to provide. Cohort 1 also included sustained periods of improvement in motor function in individual patients on exploratory clinical measures. The randomized, double-blind, placebo-controlled trial includes single-ascending-dose (five cohorts of eight) and multiple-ascending-dose components, and spans sites in the U.S., Australia, South Korea, and Taiwan. Serina expects topline single-ascending-dose data in the first half of 2027.
Serina Therapeutics (NYSE American: SER) reported second quarter 2026 results and clinical progress for SER-252, its POZ-based apomorphine candidate for Parkinson’s disease. Enrollment and dosing of all eight patients in Cohort 1 of the Phase 1b registrational study were completed in July 2026, ahead of prior guidance, with a blinded safety review and dose‑escalation decision to follow. Top‑line data from the single‑ascending‑dose arm are targeted for the first half of 2027.
Serina entered a development partnership with Gannet BioChem for SER‑252 process development, scale‑up and manufacturing, and appointed Farrell Simon, Pharm.D., to its Board and key committees. For Q2 2026, operating expenses rose to $6.8 million from $5.7 million, and net loss attributable to common shareholders was $8.9 million, or $(0.55) per share, versus $6.6 million, or $(0.66) per share, in 2025. Cash and cash equivalents increased to $23.0 million at June 30, 2026, up from $3.1 million at year‑end 2025, driven primarily by $31.3 million of financing inflows in the first half of 2026.
Serina Therapeutics (NYSE American: SER) announced that its management will participate in the BTIG Virtual Biotechnology Conference, held July 28-29, 2026, and will host virtual one-on-one investor meetings on Wednesday, July 29, 2026, arranged through BTIG representatives.
The company highlights its proprietary POZ Platform, a poly(2-oxazoline)-based polymer technology designed to optimize drug loading and controlled release for subcutaneous delivery, including a non-exclusive license agreement with Pfizer for use in lipid nanoparticle formulations. Serina also features SER-252, an investigational POZ-apomorphine therapy aiming to provide continuous dopaminergic stimulation in Parkinson’s disease.
Serina Therapeutics (NYSE American: SER) reported completion of enrollment and dosing of all eight patients in Cohort 1 of its ongoing Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease, ahead of prior guidance to finish by the end of the third quarter of 2026.
The randomized, double-blind, placebo-controlled study includes single-ascending-dose (five cohorts of eight, n=40) and multiple-ascending-dose parts (up to three cohorts of sixteen, n=48) to assess safety, tolerability and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures such as MDS-UPDRS motor scores. An independent Safety Monitoring Committee will now conduct a blinded review of Cohort 1 data to inform the next dose-escalation step. Trial sites are in the United States and Australia, with plans to add locations in South Korea and Taiwan.
Serina Therapeutics (NYSE American: SER) appointed biotech and pharma executive Farrell Simon, Pharm.D., to its Board of Directors, effective immediately, and named him to the Audit and Compensation Committees. Simon is Chief Commercial Officer at Trevi Therapeutics, where he leads commercial strategy, lifecycle management, pre-commercial planning, and business development, and has supported financings totaling more than $400 million from investors including Frazier, Vivo, Venrock and Viking. He previously spent a decade at Pfizer in senior commercial and strategic roles and holds a Pharm.D. and MBA in Finance from the University of Florida.
Serina also outlined the design of SER-252-1b, a randomized, double-blind, placebo-controlled Phase 1b study in adults with Parkinson’s disease and motor fluctuations, assessing single- and multiple-ascending subcutaneous doses of SER-252 versus placebo (up to 88 patients total). The trial will evaluate safety, tolerability and pharmacokinetics, with exploratory efficacy endpoints such as MDS-UPDRS motor scores, and is being run in the US and Australia with planned expansion to South Korea and Taiwan. The company highlighted its POZ Platform, based on poly(2-oxazoline) polymers designed to improve drug loading and release profiles for well-understood drugs with challenging pharmacokinetics, and referenced a non-exclusive license agreement allowing Pfizer to use its POZ polymer technology in lipid nanoparticle drug delivery.
Serina Therapeutics (NYSE American: SER) reported completion of sentinel dosing in Cohort 1 of its Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. An independent Safety Monitoring Committee recommended continued dosing, and additional patients are now being dosed in the US and Australia.
Serina now expects to finish Cohort 1 enrollment and dosing ahead of prior guidance of the end of the third quarter of 2026, subject to ongoing trial execution.
Serina Therapeutics (NYSE American: SER) reported Q1 2026 results and business updates. Operating expenses were $6.3 million and net loss was $6.9 million, or $(0.58) per share. Cash and cash equivalents totaled $24.5 million at March 31, 2026.
The Phase 1b registrational study of SER-252 in advanced Parkinson’s disease is underway, with Cohort 1 enrollment and dosing expected to complete by Q3 2026 and SAD TFL data targeted for the first half of 2027.
Serina closed a $21.2 million private placement in March and April 2026, and received an additional $5.2 million of gross proceeds in April 2026.
Serina Therapeutics (NYSE American: SER) will present at the 5th LNP Formulation & Process Development Summit on April 7, 2026 in Boston.
Presentation titled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform" will show that Serina’s POZ-lipid failed to elicit an antibody response in a vaccine-format rat study and previews a polymer‑lipid designed to bind diverse oligonucleotide payloads. Serina is also advancing POZ replacements for ionizable lipids to address LNP safety and versatility concerns.
Serina Therapeutics (NYSE American: SER) said NYSE American accepted its plan for continued listing compliance and granted a cure period through July 9, 2027. The company previously reported $1.6 million in stockholders' equity and multi-year losses. Serina will remain listed and face quarterly monitoring while it works to regain conformity; failure to comply could trigger suspension and delisting.